Enterococcus Bacteremia: Causes, Endocarditis, and VRE

Enterococcus bacteremia is a bloodstream infection caused by enterococci, bacteria that normally live harmlessly in the human gut but can turn dangerous when they reach the blood. It ranks among the most common hospital-acquired bloodstream infections and carries a 30-day mortality that hovers around 20% in most large studies, making it a genuinely life-threatening condition. The two species responsible for the vast majority of cases, Enterococcus faecalis and Enterococcus faecium, behave differently enough that clinicians treat them as near-separate diseases, and whether the strain is resistant to vancomycin changes the treatment calculus further still.

How Enterococci Reach the Bloodstream

Enterococci colonize the gastrointestinal tract of virtually all humans. Under normal circumstances your immune system and the rest of your gut microbiome keep them in check. The trouble starts when mucosal barriers break down, whether from surgery, inflammation, a catheter, or chemotherapy. Once enterococci cross the gut wall or enter through another compromised site, they can seed the bloodstream.

The most common portal of entry is the urinary tract, accounting for roughly a quarter of cases in classic studies, followed by intra-abdominal sources like biliary infections and peritonitis, and then wounds including burns and pressure ulcers.¹ Central venous catheters are another frequent culprit, especially in patients receiving prolonged intravenous nutrition or chemotherapy. Knowing the source matters because removing or draining it, a concept clinicians call “source control,” is often as important as the antibiotics themselves.

E. faecalis Versus E. faecium

Although both species cause bloodstream infections, they tend to show up in different clinical situations. A large prospective multicenter study found that E. faecium bacteremia was independently associated with prior use of penicillin-type or carbapenem antibiotics, hospital-acquired onset, and a biliary tract source of infection. E. faecalis, on the other hand, was more likely in patients with heart failure, cerebrovascular disease, or a urinary tract source.²

The practical significance of this split is enormous. E. faecalis usually remains susceptible to ampicillin, which means clinicians have a relatively cheap, well-tolerated drug to lean on. E. faecium is far more likely to carry intrinsic and acquired resistance, including vancomycin resistance, which limits treatment options to agents like linezolid or daptomycin. So the first question any clinician asks when enterococcal blood cultures turn positive is: which species?

The Endocarditis Question

One of the most critical complications of enterococcal bacteremia is infective endocarditis, an infection of the heart valves. Among patients with E. faecalis bacteremia specifically, a landmark study found definite endocarditis in about 26% of cases, a rate high enough that the authors recommended echocardiography for all patients with E. faecalis in their blood.³ That one-in-four figure is startling and is much higher than for most other bacteria that cause bloodstream infections.

Because performing transesophageal echocardiography on every single patient is resource-intensive and not risk-free, several clinical scoring systems have been developed to identify which patients are at highest risk. The NOVA score, one of the earliest, uses variables like the Number of positive blood cultures, Origin of infection, prior Valve disease, and Auscultation findings to stratify risk.⁴ A newer score, the DENOVA, was externally validated in a cohort of 543 patients and showed strong discrimination, with a sensitivity of about 79% and specificity of 83% at its recommended cutoff. Decision-curve analysis confirmed that using the DENOVA score reduced unnecessary echocardiograms while still catching most cases of endocarditis.⁵

A recent comparison across 827 episodes of enterococcal bacteremia found that the adapted NOVA and DENOVi scores had very low negative likelihood ratios, meaning they were good at ruling out endocarditis when the score was low. However, the adapted NOVA classified a large share of patients (76%) as high risk, which somewhat defeats the purpose of a triage tool.⁶ The DENOVA score appears to strike a better balance, classifying a smaller proportion as high risk while still catching most true endocarditis cases. No score is perfect, and clinicians still use their judgment alongside these tools.

Treating E. faecalis Endocarditis

For decades, the standard treatment for E. faecalis endocarditis was ampicillin combined with an aminoglycoside, typically gentamicin. This combination works because enterococci are inherently tolerant to cell-wall-active antibiotics alone and need a second drug to achieve bacterial killing. The problem is that gentamicin is hard on the kidneys. In a pivotal multicenter study comparing ampicillin plus ceftriaxone against ampicillin plus gentamicin, mortality was essentially identical between the two regimens (about 22% versus 21% during treatment), but the gentamicin arm caused new kidney injury in 23% of patients, compared with 0% in the ceftriaxone arm.⁷

A subsequent propensity-matched retrospective analysis reinforced those findings, showing no significant difference in 90-day mortality between the two regimens but far more adverse events and treatment switches in the gentamicin group.⁸ As a result, ampicillin plus ceftriaxone has become the preferred regimen in many institutions, sparing patients weeks of nephrotoxic therapy. The combination also has a practical advantage: it works regardless of whether the E. faecalis strain has high-level aminoglycoside resistance, a trait that renders gentamicin useless.

Vancomycin-Resistant Enterococci and Drug Options

Vancomycin-resistant enterococci, usually E. faecium, pose a different therapeutic puzzle. When ampicillin and vancomycin are both off the table, clinicians are left with linezolid, daptomycin, or newer agents like oritavancin and tedizolid that have less clinical outcome data. The head-to-head data on linezolid versus daptomycin have gone back and forth.

One retrospective comparison found that patients treated with standard-dose daptomycin had a clinical failure rate roughly 1.5 times that of linezolid-treated patients, with an adjusted odds ratio of about 2.9 for failure.⁹ That study highlighted a key nuance: the daptomycin dose matters. Standard dosing (6 mg/kg) may be inadequate for VRE bloodstream infections, and many experts now recommend higher doses in the range of 8 to 12 mg/kg.

Meta-analyses paint a more balanced picture. One systematic review found that daptomycin was associated with higher mortality compared to linezolid overall, but when subgroup analysis focused on studies using high-dose daptomycin, the mortality difference disappeared.¹⁰ An earlier meta-analysis similarly found that daptomycin was associated with higher mortality but noted the observational nature of all included studies.¹¹ Each drug carries its own side-effect profile: linezolid can cause dangerously low platelet counts with prolonged use, while daptomycin can elevate creatine kinase and cause muscle toxicity. The choice often comes down to what other problems the patient has and how long the treatment course needs to be.

How Vancomycin Resistance Spreads

The genes that confer vancomycin resistance, principally vanA and vanB, sit on mobile genetic elements that can hop between bacteria. This is one reason VRE outbreaks are so difficult to contain once they take hold in a hospital unit. There has been interest in whether bacteria might also share these genes through membrane vesicles, tiny bubble-like structures that cells shed naturally. A study investigating this route was able to detect the vancomycin resistance genes inside membrane vesicles produced by resistant E. faecium, but the vesicles did not actually confer resistance to susceptible bacteria in lab conditions.¹² The more established routes of gene transfer, particularly conjugation (direct cell-to-cell transfer of DNA), remain the dominant concern.

What makes the resistance problem even more alarming is that enterococci can adapt in real time inside a patient’s body. Genome sequencing of E. faecalis isolates taken from the same patient over the course of an infection has revealed repeated independent mutations in a small number of genes, suggesting the bacteria are evolving under the pressure of antibiotics and the host immune system simultaneously. Some of these mutations made the bacteria better at surviving both antibiotic treatment and the innate immune defenses encountered in blood.¹³

When the Infection Will Not Clear

Persistent bacteremia, defined as blood cultures that remain positive after several days of appropriate antibiotics, is a dreaded development in enterococcal bloodstream infections. In one multicenter retrospective study, about 14% of patients with enterococcal bacteremia met the definition for persistent infection. The independent risk factors included blood cancers, endocarditis, and initial treatment with daptomycin. Thirty-day mortality in the persistent group was nearly double that of the non-persistent group, at 32% versus 18%.¹⁴

A key unresolved question is whether persistent bacteremia itself drives worse outcomes or whether it is simply a marker of more severe underlying illness. A state-of-the-art review noted that patients with persistent bacteremia tend to have higher rates of cancer, neutropenia, and uncontrolled sources of infection, making it difficult to tease apart cause and effect.¹⁵ A study focused on persistent VRE bacteremia specifically found that severe neutropenia, all four initial blood culture bottles turning positive, and lack of source control were the strongest risk factors for prolonged infection.¹⁶ Regardless of whether the persistence itself is doing the damage, it should be treated as a red flag that demands aggressive re-evaluation: Is there a collection that needs draining? Is the antibiotic actually reaching the infection? Should imaging for endocarditis be repeated?

Polymicrobial Cases

Enterococcal bloodstream infections are frequently polymicrobial, meaning another bacterium shows up alongside the enterococcus. This is common with intra-abdominal infections, where the gut’s diverse microbial ecosystem can spill into the bloodstream. A reasonable assumption might be that two bacteria in the blood are worse than one, but a matched comparison of 142 pairs found no significant difference in 30-day mortality between polymicrobial and monomicrobial enterococcal bloodstream infections (about 21% versus 18%).¹⁷ The presence of a second organism does not appear to independently worsen the prognosis, though it does complicate antibiotic selection because both organisms need to be covered.

Faster Identification, Better Outcomes

One of the practical bottlenecks in managing enterococcal bacteremia is the time it takes to identify the specific species and its resistance pattern from a blood culture. Traditional methods can take a day or more after the culture first flags positive. Newer technology using mass spectrometry (MALDI-TOF) can identify bacteria directly from a positive blood culture bottle in roughly an hour. In a controlled clinical trial, this rapid identification cut the average time from initial Gram stain to effective antibiotic therapy from about 6.7 hours to 3.7 hours for clinically significant infections.¹⁸

For enterococcal infections specifically, this speed advantage has a meaningful clinical payoff. A study focused on enterococcal bloodstream infections found that rapid identification led to more frequent antibiotic adjustments, including both de-escalation (stepping down to narrower drugs when the species turned out to be susceptible) and appropriate escalation when a resistant species was identified.¹⁹ Getting the species answer faster matters here more than for many other bacteria, precisely because the treatment difference between E. faecalis and E. faecium is so large.

Infection Control and Environmental Contamination

VRE is notoriously hardy in hospital environments. The bacteria can survive on dry surfaces for days to weeks, which means a patient room cleaned inadequately between occupants can become a source of transmission. An intervention study in a medical intensive care unit found that enforcing routine environmental cleaning measures cut VRE acquisition by roughly two-thirds, from about 33 cases per 1,000 patient-days to around 10.²⁰

The type of cleaning agent matters too. In a study that cultured environmental surfaces in rooms of VRE-positive patients, standard housekeeping cleaning left about 71% of rooms still contaminated, while bleach disinfection by research staff eliminated all detectable VRE.²¹ Hand hygiene, contact precautions (gowns and gloves when entering the room), and active surveillance cultures in high-risk units are all part of the bundle most hospitals deploy, but the environmental cleaning piece is sometimes the weakest link.

Fecal Microbiota Transplant for VRE Decolonization

Patients who carry VRE in their gut remain at risk for future bloodstream infections, especially if they undergo chemotherapy or major surgery. Getting rid of VRE from the gut has proven stubbornly difficult. There is no reliable antibiotic regimen for decolonization, and VRE can persist in the intestinal tract for months to years. An emerging strategy is fecal microbiota transplant (FMT), which essentially re-introduces a healthy community of gut bacteria that can outcompete VRE.

The data are still early. A pilot study of six patients found that half achieved VRE decolonization lasting more than six months after FMT.²² A slightly larger case series reported decolonization in seven of eight patients at three months.²³ A systematic review pooling available data found a 12-month decolonization rate of about 53% in FMT recipients versus 13% in controls.²⁴ These numbers are promising but come from very small studies. FMT for VRE decolonization is not yet standard practice, and important questions remain about optimal donor screening, timing, and which patients benefit most.

Neonatal Intensive Care Units

VRE outbreaks in neonatal intensive care units (NICUs) deserve separate mention because the population is uniquely vulnerable. Newborns have immature immune systems and often require prolonged courses of broad-spectrum antibiotics, both of which favor VRE colonization. During one NICU outbreak, screening found that 40% of neonates were colonized with VRE. The strongest risk factors were receipt of antibiotics for late-onset sepsis and hospitalization during the early phase of the outbreak, when control measures had not yet been implemented.²⁵ NICU outbreaks highlight how quickly VRE can spread in a closed unit with vulnerable patients and high antibiotic use.

Neutropenia and Immune Status

Patients with cancer, especially blood cancers, make up a disproportionate share of enterococcal bacteremia cases. Chemotherapy often destroys the gut lining and suppresses the immune system simultaneously, creating ideal conditions for gut bacteria to enter the bloodstream. You might expect that vancomycin resistance would be especially lethal in these already-fragile patients, but one study looking specifically at neutropenic patients found that vancomycin resistance itself did not significantly affect the fatality rate when compared to vancomycin-susceptible enterococcal bloodstream infections.²⁶ This was a somewhat surprising finding, and the authors noted that other factors such as the severity of the underlying malignancy and how sick the patient was at baseline mattered more than the resistance profile. It does not mean vancomycin resistance is irrelevant, but it reinforces that in the sickest patients, host factors tend to dominate the outcome equation.

The Animal Reservoir

Enterococci are not just a hospital problem. Multidrug-resistant strains, including those genetically related to strains that cause human infections, have been found in livestock farming environments. A molecular study of pig farms detected enterococcal clones associated with human infections in manure, waste lagoons, drinking water, and animal feed on the same farm. Some of the same high-risk lineages appeared on farms that were geographically distant from one another, suggesting widespread dissemination through the agricultural supply chain.²⁷ The continuous exposure of livestock to resistant enterococci through contaminated feed, water, dust, and housing may undermine efforts to curb resistance through antibiotic stewardship alone. Addressing the animal reservoir will likely require changes at the farm-management level, not just at the hospital bedside.